Methimazole is an antithyroid medication used primarily to treat hyperthyroidism, a condition in which the thyroid gland produces too much hormone. It is the most widely prescribed antithyroid drug in the United States and in most countries worldwide, with annual prescriptions growing roughly ninefold between 1991 and 2008. While Graves’ disease accounts for the bulk of methimazole prescriptions, the drug also plays a role in preparing patients for radioactive iodine therapy or surgery, managing thyroid emergencies, treating certain drug-induced forms of thyrotoxicosis, and even controlling overactive thyroids in cats.
How Methimazole Lowers Thyroid Hormone
The thyroid gland relies on an enzyme called thyroid peroxidase to build its hormones, T3 and T4. Methimazole interferes with that enzyme, blocking the chemical steps needed to incorporate iodine into the hormone precursors. What makes methimazole particularly effective is that its inhibition of the enzyme is essentially irreversible under normal conditions: once it binds, increasing the enzyme’s usual fuel (hydrogen peroxide) does not restart the process.1PubMed Central. Anti-thyroid drugs and thyroid hormone synthesis: effect of methimazole derivatives on peroxidase-catalyzed reactions The practical result is a steady decline in circulating thyroid hormone levels over weeks, bringing the overactive gland back toward normal output.
Because methimazole blocks hormone production but does not destroy thyroid tissue, the gland remains intact. That is a meaningful distinction from radioactive iodine or surgery, both of which permanently reduce or eliminate the thyroid’s ability to make hormone. With methimazole, the hope is that the underlying autoimmune process driving the overproduction will eventually burn out on its own, allowing the drug to be stopped.
Graves’ Disease and Long-Term Therapy
Graves’ disease is the most common cause of hyperthyroidism and the condition for which methimazole is most often prescribed. The traditional approach has been to use methimazole for about 18 to 24 months, then taper off and see whether the disease stays in remission. That conventional course works for some patients, but relapse rates have historically been disappointing, with many people seeing their hyperthyroidism return within a few years of stopping treatment.
A randomized clinical trial found that extending low-dose methimazole therapy to 60 to 120 months produced much higher remission rates than the standard 18-to-24-month course.2PubMed. Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves’ Disease: Results of a Randomized Clinical Trial These findings have shifted the conversation in endocrinology: for patients who tolerate methimazole well, continuing it for several years at a low dose may be a reasonable strategy, potentially sparing them from radioactive iodine or surgery altogether.
The same pattern holds in children. A randomized trial of juvenile Graves’ disease compared long-term methimazole (96 to 120 months) with the conventional shorter course. Among children treated for the longer period, about nine in ten were cured one year after stopping the drug, compared with fewer than half in the short-treatment group. The required daily dose dropped steadily over time, and serious side effects were rare, limited to a few skin reactions across the entire study.3Pediatrics. Long-term Methimazole Therapy in Juvenile Graves’ Disease: A Randomized Trial For parents weighing the options for a child with Graves’ disease, the prospect of a long but low-dose medication course that avoids permanent thyroid destruction is an appealing one.
What Predicts Relapse After Stopping
Not everyone who finishes a course of methimazole stays in remission, and knowing who is most likely to relapse helps guide how long to continue therapy. Several features at the time of drug withdrawal raise the odds that hyperthyroidism will return: a larger goiter, persistent thyroid-stimulating antibodies, and a history of prior Graves’ disease episodes. Additionally, patients whose thyroid-stimulating hormone levels stayed suppressed during the maintenance phase were more prone to relapse.4PubMed. Valuable predictive features of relapse of Graves’ disease after antithyroid drug treatment In practice, these risk factors help clinicians decide whether to push for a longer treatment course or shift to a more definitive option like radioactive iodine.
Preparing for Radioactive Iodine
Many patients with Graves’ disease or toxic nodular goiter ultimately receive radioactive iodine to destroy overactive thyroid tissue. Methimazole is frequently used in the weeks before that procedure to stabilize hormone levels and reduce the risk of a dangerous flare during or after treatment. A natural concern is whether giving methimazole beforehand might make the radioactive iodine less effective by partially shielding the gland.
A systematic review and meta-analysis addressed that question directly. When methimazole was used alongside radioactive iodine and then discontinued, the risk of persistent hyperthyroidism afterward was essentially the same as when radioactive iodine was used alone. A subgroup analysis suggested that stopping methimazole within about a week before radioactive iodine administration might even slightly lower the risk of persistent disease, though the difference was not large enough to be statistically certain.5PubMed Central. Efficacy of methimazole before the administration of radioactive iodine in the management of Graves’ disease: a systematic review and meta-analysis The practical takeaway is that using methimazole to keep a patient stable before radioactive iodine treatment does not compromise the procedure’s effectiveness, as long as the drug is stopped around the time of the iodine dose.
Thyroid Storm
Thyroid storm is a rare but life-threatening escalation of hyperthyroidism, marked by dangerously high heart rates, fever, and sometimes organ failure. Antithyroid drugs are a cornerstone of emergency treatment because they directly halt further hormone production. American Thyroid Association guidelines recommend propylthiouracil (PTU) rather than methimazole as first-line therapy in this setting, largely because PTU has an additional action that methimazole lacks: it blocks the conversion of T4 to the more active T3 outside the thyroid gland, potentially lowering circulating T3 faster.6JAMA Network Open. Comparison of Propylthiouracil vs Methimazole for Thyroid Storm in Critically Ill Patients
That said, methimazole is still used in thyroid storm when PTU is unavailable or when a patient has had a prior reaction to it. In some hospitals, methimazole is the only antithyroid drug stocked. The evidence comparing the two drugs head-to-head in critically ill patients with thyroid storm remains limited, so the preference for PTU in this scenario leans more on pharmacological reasoning than on large randomized trials.
Methimazole Versus Propylthiouracil for Routine Hyperthyroidism
Outside of thyroid storm and pregnancy, methimazole has largely replaced PTU as the preferred antithyroid drug for day-to-day management of hyperthyroidism. One important practical advantage is dosing convenience. A single daily dose of methimazole controls thyroid hormone levels more effectively than a single daily dose of PTU. In a head-to-head trial, 15 mg of methimazole taken once daily brought about three-quarters of patients to normal thyroid levels within 12 weeks, compared with fewer than one in five on a single daily 150 mg dose of PTU.7PubMed Central. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism PTU is typically dosed two or three times per day for adequate effect, which makes adherence harder for patients. Methimazole also carries a lower risk of severe liver injury compared with PTU, which has been linked to rare but sometimes fatal liver failure.
These differences drove a dramatic shift in prescribing patterns. In the early 1990s, PTU held about two-thirds of the U.S. antithyroid drug market. By the mid-1990s methimazole had overtaken it, and by 2008 methimazole prescriptions had climbed to roughly 1.36 million per year while PTU held relatively steady around 415,000.8The Journal of Clinical Endocrinology & Metabolism. Shifts in Propylthiouracil and Methimazole Prescribing Practices: Antithyroid Drug Use in the United States from 1991 to 2008
Pregnancy and When PTU Is Preferred
Pregnancy is the major exception to the general rule that methimazole is the better choice. Methimazole use during the first trimester has been associated with a specific cluster of birth defects, including skin abnormalities called aplasia cutis and, less commonly, malformations of the esophagus and other structures.9PubMed. Malformations following methimazole exposure in utero: an open issue Endocrine Society guidelines recommend PTU as the first-line drug for thyrotoxicosis during pregnancy because of these associations.10QJM: An International Journal of Medicine. Carbimazole embryopathy: implications for the choice of antithyroid drugs in pregnancy
Many endocrinologists switch women who are planning pregnancy or who discover they are pregnant from methimazole to PTU for the first trimester, then switch back to methimazole in the second trimester once the window of greatest teratogenic risk has passed and PTU’s liver toxicity risk becomes the more pressing concern. It is a balancing act between two imperfect options, but current guidance is clear that methimazole should be avoided during early pregnancy when an alternative is available.
Amiodarone-Induced Thyrotoxicosis
Amiodarone is a widely used heart-rhythm drug that is loaded with iodine and can push the thyroid into overdrive in susceptible patients. This condition, called amiodarone-induced thyrotoxicosis (AIT), comes in two main forms. Type 1 occurs when the excess iodine fuels overproduction of thyroid hormone in a gland that already has underlying disease. Methimazole-based therapy is the first-line treatment for type 1 AIT, though the iodine-saturated gland tends to be less responsive to antithyroid drugs than it otherwise would be. Adding potassium perchlorate, which blocks further iodine uptake by the thyroid, can improve the response.11The Journal of Clinical Endocrinology & Metabolism. Approach to the Patient with Amiodarone-Induced Thyrotoxicosis
Case reports have documented successful treatment of type 1 AIT using methimazole combined with potassium iodide, even in patients with complex underlying thyroid conditions like Hashimoto’s thyroiditis.12PubMed Central. Successful Treatment of Amiodarone-induced Thyrotoxicosis Type 1 in Combination with Methimazole and Potassium Iodide in a Patient with Hashimoto’s Thyroiditis Managing AIT is often tricky because stopping amiodarone is not always an option in patients with serious heart-rhythm disorders, and the drug’s extremely long half-life means its effects linger for months after discontinuation.
Side Effects and Risks
Most people tolerate methimazole well, especially at lower doses. The most common complaints are relatively mild and include itching, hives, and joint pain. In a study of children on methimazole for Graves’ disease, skin-related reactions like hives and itching were the most frequent adverse events, and joint pain occurred in a smaller number.13PubMed Central. Adverse events associated with methimazole therapy of graves’ disease in children These minor reactions often resolve on their own or with dose adjustments.
The rare side effects are the ones that demand vigilance. Agranulocytosis, a sudden and dangerous drop in white blood cells, is the most feared complication. It can leave a patient unable to fight infections and typically presents with fever, sore throat, or mouth sores. The onset is abrupt, and patients starting methimazole should be told to seek immediate medical attention if those symptoms appear. If blood work confirms the white-cell count has dropped, the drug must be stopped right away. Switching to PTU is not recommended as a workaround, because cross-reactivity between the two drugs has been observed.14Endocrinology Insights. Methimazole-Induced Agranulocytosis: A Clinical Case Report Once the causative drug is discontinued, recovery can be supported with growth factor injections and antibiotics, and the white blood cell count usually rebounds within a couple of weeks.15PubMed Central. Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management
Liver injury is another rare but serious possibility. While PTU tends to cause a more dangerous pattern of direct liver cell destruction, methimazole is more associated with cholestatic injury, where bile flow is obstructed rather than liver cells being killed outright. A case report described a young woman who developed severe itching and jaundice just 13 days after starting methimazole for newly diagnosed Graves’ disease. Her liver function tests eventually normalized, but the process took about two years.16PubMed Central. Methimazole-Induced Cholestatic Jaundice: A Rare Case and Literature Review The rarity of this reaction means routine liver monitoring is not universally practiced, but patients should be aware that new-onset jaundice, dark urine, or unexplained abdominal pain on methimazole warrants immediate evaluation.
Interactions with Warfarin and Other Drugs
Thyroid hormone levels influence how fast the body breaks down proteins, including the clotting factors that warfarin works on. When a person with hyperthyroidism starts methimazole and their thyroid hormone levels begin to fall, the rate at which clotting factors are metabolized slows down. That means the same dose of warfarin can suddenly produce a stronger anticoagulant effect than before, raising the risk of bleeding. The reverse can also happen: if methimazole is stopped and hyperthyroidism returns, warfarin may seem to lose effectiveness.17PubMed. Effect of Graves’ disease and methimazole on warfarin anticoagulation Anyone on warfarin who starts, stops, or changes the dose of methimazole needs more frequent blood-clotting checks during the transition.
This interaction extends to other medications whose metabolism is affected by thyroid status. Beta-blockers, for example, are often prescribed alongside methimazole to control the fast heart rate of hyperthyroidism. As thyroid levels normalize, the beta-blocker dose usually needs to be reduced. Diabetes medications may also need adjustment, since thyroid hormones affect blood sugar regulation. The general principle is that any time methimazole meaningfully shifts thyroid function, the doses of other medications should be re-evaluated.
Use in Cats
Methimazole is not just a human drug. Hyperthyroidism is the most common endocrine disorder in older cats, and methimazole is the standard medical treatment. Most cat owners are familiar with the twice-daily pill that needs to be wrestled into a reluctant feline. A transdermal formulation, applied to the inside of the ear, has become a popular alternative because it avoids the gastrointestinal upset that oral dosing can cause.
Studies of transdermal methimazole in cats have found it to be effective at controlling thyroid hormone levels, though the response may be slightly slower than with oral dosing in the first couple of weeks. By four weeks, the difference in effectiveness between the two routes is no longer clear. The transdermal route does appear to cause fewer digestive side effects like vomiting and loss of appetite.18Journal of Veterinary Internal Medicine. Efficacy and Safety of Transdermal Methimazole in the Treatment of Cats with Hyperthyroidism Additional clinical work has confirmed transdermal methimazole as a safe and effective alternative to conventional oral formulations for feline hyperthyroidism.19PubMed Central. Clinical efficacy and safety of transdermal methimazole in the treatment of feline hyperthyroidism For cat owners who have tried and failed to pill their pet twice daily, the ear gel can be the difference between manageable treatment and an impossible routine.
Cats on long-term methimazole need regular blood work, including kidney function tests. Hyperthyroidism can mask underlying kidney disease by increasing blood flow through the kidneys. As methimazole brings thyroid levels down, previously hidden kidney problems sometimes surface. This does not mean the drug is harming the kidneys; rather, it is unmasking a problem that was already there. Veterinarians typically check kidney values within the first few weeks of starting methimazole to make sure the cat’s kidneys can handle normal thyroid function.